Neumonólogo. Latinoamericano, Venezolano, Caraqueño y Guayaco de adopción. Papá de Coco y Nana Director Departamento EPOC @alatorax 2024-2026.
Guayaquil, Guayas, Ecuador.
Joined January 2010
- Tweets48.9K
- Following989
- Followers1.4K
- Likes460
Efraín J. Sánchez Angarita retweeted
A new study found that many bronchiectasis patients are not prescribed high frequency chest wall oscillation therapy to improve mucus removal even though it can be reimbursed for many patients. Read more in the Journal of the COPD Foundation: journal.copdfoundation.org/j…
Efraín J. Sánchez Angarita retweeted
Quiero agradecer al presidente Florentino Pérez y a la Junta que me hayan propuesto formar parte de la Junta Directiva del @realmadrid.
He aceptado esta propuesta con mucha ilusión, ganas de aprender y aportar todo lo que pueda.
🤍🤍🤍
Comunicado Oficial: Rafael Nadal.
realmadrid.com/es-ES/noticia…
Efraín J. Sánchez Angarita retweeted
💬“Patient with #Sjögren's and #bronchiectasis represent a unique population,” Adrienne Strait, MD, @StanfordMed, said at #CHEST2026.
vist.ly/5r8xn
Efraín J. Sánchez Angarita retweeted
Three major October headlines from studies published in NEJM:
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI
2️⃣ In small trial, optogenetics restores some vision lost to retinitis pigmentosa (STAT) nej.md/4imhuUB
Original Article: Optogenetic Therapy for Restoring Aspects of Visual Function (PIONEER) nej.md/4j18UMZ
3️⃣ Glucose Monitors Can Help Type 2 Diabetics Who Don't Yet Need Insulin, Trial Shows (HealthDay) nej.md/3WSd6W4
Original Article: Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes (CONNECT) nej.md/3TGQNlg
Explore impactful research at NEJM.org.
Efraín J. Sánchez Angarita retweeted
#Lungcancer is the world’s leading cause of cancer deaths, and its diagnosis remains challenging. Our mission is to empower physicians to achieve an earlier, more definitive diagnosis.
Learn how Cellvizio advanced imaging improves diagnostic accuracy: hubs.la/Q04D5RQy0
Efraín J. Sánchez Angarita retweeted
We shouldn't underestimate the power of vagus nerve modulation. Today the potential for Parkinson's disease. Noninvasively.
Work in the experimental model @natBME
nature.com/articles/s41551-0…
Efraín J. Sánchez Angarita retweeted
🫁 Tabaquismo y vapeo en jóvenes
La exposición temprana a nicotina y aerosoles tóxicos puede afectar el desarrollo pulmonar y aumentar el riesgo de dependencia. Vapear no es una alternativa segura.
🔬 Conoce más:
alatorax.org/r/sFD8mD/x
Efraín J. Sánchez Angarita retweeted
Should AI of cardiac MRI be the first-line read, prior to clinicians? A study on determining ejection fraction with survival outcomes @LancetDigitalH
thelancet.com/journals/landi…
Efraín J. Sánchez Angarita retweeted
Discovery of a mechanism to help explain why pulmonary hypertension is linked to cognitive decline.
Multiple cohorts and mouse model work shows inflammation (both microglia and endothelial) and a specific mediator @jclinicalinvest
jci.org/articles/view/212006
jci.org/articles/view/195110
Efraín J. Sánchez Angarita retweeted
Original Article: Tozorakimab to Prevent COPD Exacerbations (phase 3 OBERON and TITANIA trials) nej.md/4zNqtWJ
#Pulmonology #CriticalCare
ALT Three figures show data for the patients in the OBERON and TITANIA trials who were assigned to receive tozorakimab every 4 weeks and those who were assigned to receive placebo. Panel A is a forest plot that shows the annualized rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations that had occurred over a 52-week period among former smokers (the primary end point) and in the overall population, which consisted of current and former smokers (the first key secondary end point). Panel B displays two graphs that show the cumulative mean number of moderate or severe exacerbations that occurred over a 52-week period in the overall population.
Efraín J. Sánchez Angarita retweeted
NOVEMBER is COPD Awareness Month 🧡This year, we're celebrating the power of ORANGE as a symbol of the movement to improve lung health.
Join us this month as we shine a light on COPD.
#COPDAwarenessMonth #November #OrangeIs #COPD #Orange #LungHealth #Advocacy
Efraín J. Sánchez Angarita retweeted
On World COPD Day, Wednesday, November 18, one baton travels around the world for 24 hours. Patients, families, clinicians and scientists from around the world are coming together to raise awareness for COPD.
Add your voice! Film a 30-second selfie about why COPD matters to you, end with "I am passing the baton on," and upload it here: bit.ly/48o9iyh.
Heading to the GOLD COPD Conference in Philadelphia on November 5 and 6? Stop by the "Pass It On" booth and film your video live!
For more on World COPD Day, visit bit.ly/4kpcp06
#COPDBatonPass #WorldCOPDDay
Efraín J. Sánchez Angarita retweeted
Here is the clip of the Brewers on SNL tonight:
Pat Murphy, Christian Yelich, Brice Turang…and Drunk Uncle👇🤣
🎥: SNL
Efraín J. Sánchez Angarita retweeted
More therapeutic options for patients living with #COPD regardless of baseline blood eos
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new Quick Take video. nej.md/47Edhqp
ALT A visual representation of the OBERON and TITANIA trials, which assessed tozorakimab, a monoclonal antibody that inhibits interleukin-33, to reduce COPD exacerbations.
Efraín J. Sánchez Angarita retweeted
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new Quick Take video. nej.md/47Edhqp
ALT A visual representation of the OBERON and TITANIA trials, which assessed tozorakimab, a monoclonal antibody that inhibits interleukin-33, to reduce COPD exacerbations.
Efraín J. Sánchez Angarita retweeted
ERJ Open Research: Patients with COPD–obstructive sleep apnoea (OSA) overlap syndrome have a significantly higher cardiovascular mortality compared with OSA alone but not compared with COPD alone, necessitating earlier prevention strategies bit.ly/3QayPpz
Efraín J. Sánchez Angarita retweeted
The small-ball Milwaukee Brewers, playing in the smallest market in the majors, are World Series champions for the first time after beating the Tampa Bay Rays 4-1 in Game 5. apnews.com/article/brewers-r…
Efraín J. Sánchez Angarita retweeted
Given that biologics main target is to reduce type 2 inflammation, why is a spirometry-based exclusion necessary? This study shows that criteria based on elevated type 2 biomarkers, and exacerbation history enrich trial populations likely to benefit from biologics.
European Respiratory Journal: Spirometry-based exclusions have limited influence on biologic treatment response and unduly restrict generalisability of clinical trials bit.ly/4wJoMYR
Efraín J. Sánchez Angarita retweeted
La EPOC es una enfermedad progresiva heterogénea sin tratamientos modificadores de la enfermedad. Modelos preclínicos in vivo, ex vivo e in silico han ayudado a obtener información sobre la EPOC. Necesitamos mejorar e integrar modelos relevantes para humanos con el fin de lograr un mejor endotipado de la EPOC. bit.ly/3QZUzVu
@ERSpublications
COPD is a progressive heterogeneous disease with no disease-modifying treatments. In vivo, ex vivo and in silico preclinical models have helped gain insight into COPD. We need to improve and integrate human-relevant models for better COPD endotyping. bit.ly/3QZUzVu
Efraín J. Sánchez Angarita retweeted
🚨 ESMO 2026 × NEJM: Is chemotherapy losing its place in first-line lung cancer?
🔥 OptiTROP-Lung06 delivers a striking Phase III result in PD-L1–negative advanced nonsquamous NSCLC!
Sacituzumab tirumotecan + pembrolizumab vs chemo + pembrolizumab:
📊 Median PFS: 15.0 vs 5.7 months
🔥 51% lower risk of progression/death (HR 0.49)
✅ Grade ≥3 AEs: 47.6% vs 60.6%
⚠️ OS remains immature.
The big question: Could TROP2-ADC + immunotherapy replace platinum chemotherapy in first line?
Published simultaneously in NEJM during #ESMO26.
@my_esmo @ESMO_open @ASCO @oncoalert
#LungCancer #NSCLC #ESMO26
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH!
From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26.
🔥 My Top 10 Trials
1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC
2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC
3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors
4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC
5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression
6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel
7.SARON | Consolidation RT in oligometastatic NSCLC
8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50%
9.DeLLphi-304 | Long-term survival with tarlatamab
10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC
Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1.
Which trial could have the biggest impact on lung cancer treatment?
@myesmo @ESMO_open @ASCO @oncoalert
#ESMO26 #LungCancer #Oncology
